bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 522,561 shares, a drop of 36.0% from the June 30th total of 816,644 shares. Approximately 11.3% of the shares of the company are sold short. Based on an average daily volume of 589,484 shares, the short-interest ratio is currently 0.9 days.

bioAffinity Technologies Price Performance

Shares of bioAffinity Technologies stock opened at $0.63 on Friday. The stock has a market cap of $2.97 million, a P/E ratio of -0.05 and a beta of -1.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.34 and a current ratio of 1.36. The stock’s fifty day moving average is $1.04 and its 200 day moving average is $1.67. bioAffinity Technologies has a one year low of $0.56 and a one year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.59. The business had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Institutional Investors Weigh In On bioAffinity Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIAF. Scientech Research LLC bought a new stake in bioAffinity Technologies during the 3rd quarter worth approximately $49,000. Geode Capital Management LLC bought a new position in shares of bioAffinity Technologies in the fourth quarter worth approximately $36,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in shares of bioAffinity Technologies in the first quarter worth $164,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BIAF shares. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. Wall Street Zen upgraded shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.